Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.

Silke Wemmert; Ralf Ketter; Jörg Rahnenführer; Niko Beerenwinkel; Martin Strowitzki; Wolfgang Feiden; Christian Hartmann; Thomas Lengauer; Florian Stockhammer; Klaus D Zang

doi:10.1593/neo.05307

Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.

Identifier:nobleid.org/w1/20260515/69BECDD2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/69BECDD2.svg?ark=w1%2F20260515%2F69BECDD2)](https://nobleid.org/work/w1/20260515/69BECDD2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work

Patients with high-grade gliomas harboring deletions of chromosomes 9p and 10q benefit from temozolomide treatment.

Identifier:nobleid.org/w1/20260515/69BECDD2

Type:Journal Article

0 views

Support unavailableClaim Your Authorship

View Original Paper Source

Embeddable Badge

[![NobleID](https://www.nobleid.org/api/badge/69BECDD2.svg?ark=w1%2F20260515%2F69BECDD2)](https://nobleid.org/work/w1/20260515/69BECDD2)

ARK Inflections

Metadata Policy

Metadata Formats

Bibliometric Analysis

Impact metrics, research fronts, co-authorship networks →

Authors & Claims

Paper Authors

Claim authorship of this work